ACE2 protein variant (Angiotensin Therapeutics)

N/A

Report date: 2025/01/26 18:30:28

Base Information

Drug NameACE2 protein variant (Angiotensin Therapeutics)
Drug Alias NameACE2 protein variant (Northwestern University)
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAngiotensin-converting enzyme 2 stimulants
TargetsAngiotensin-converting enzyme 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNorthwestern University
China Registration ClassN/A

Develop Information

Active CompaniesAngiotensin Therapeutics Inc
Inactive CompaniesNorthwestern University
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsCoronavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A